These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20375898)

  • 1. Pleural effusions due to dasatinib.
    Brixey AG; Light RW
    Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approved dasatinib regimen available for clinical use.
    Snyder DS
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
    Breccia M; Alimena G
    Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib-induced pleural effusions: a lymphatic network disorder?
    Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
    Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
    Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
    Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
    Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
    Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
    Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
    Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
    Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
    J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
    Masiello D; Gorospe G; Yang AS
    J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
    Wong SF
    J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
    Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
    Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.